Below is the full list of studies presented by Juul Labs:

• Switching Away from Combustible Cigarettes across a 12-Month Period Among Adult Smokers Who Purchased the JUUL System
• Differences in the Appeal of the JUUL System in Four Flavors between Smokers of Mentholated and Nonmentholated Combustible Cigarettes
• Longitudinal Study of Dual Use of Combustible Cigarettes and the JUUL System in Adult Current Smokers at 12 Months
• Racial/Ethnic Differences in Switching and Dual Use Behavior Among Adult Current Smokers Who Use the JUUL System
• Changes in Biomarkers of Cigarette-Smoke-Related Toxicants After 6 Days of Switching Exclusively or Partially to the JUUL System in Two Nicotine Concentrations: A Randomized Controlled Study in Adult Smokers
• Understanding the Net Population Health Impact of Electronic Nicotine Delivery Systems with Agent-Based Modeling
• The Impact of Banning ENDS Products on Combustible Cigarette Sales: Initial Evidence from U.S. State-Level Policies
• Spatial Spillover Effects of State-Level Policies Banning ENDS Products
• Dependence on JUUL System ENDS Compared to Dependence on Cigarettes: Psychometric and Comparative Analyses in US Adults

In addition to the nine posters presented by Juul Labs, consultants to Juul Labs (Pinney Associates) and an independent contract research organization (Centre for Substance Use Research) presented two studies sponsored by Juul Labs:

• Complete Switching Away from Smoking among JUUL Product Users Who Had Failed to Quit with FDA-Approved Medications, and Smokers Not Ready to Quit Smoking 
• Analyses of Loss to Follow-up in a Longitudinal Study of Smokers Using JUUL System ENDS 

To better understand patterns of tobacco product use among adult smokers, Juul Labs has developed an extensive behavioral research program that includes measurements of complete switching from combustible cigarettes to the JUUL System among adult smokers. Among the data presented at SRNT are the results of a longitudinal study which found that more than 50% of adult smokers who purchased the JUUL System reported complete switching at a 12-month follow-up assessment. Complete switching was defined as no cigarette smoking in the past 30 days — not even a puff.

Another new study presented this week examined trends in dual use of the JUUL System and cigarettes among adult smokers who recently purchased JUUL products, as well as any changes in cigarette consumption among these dual-users. While dual use of JUUL products and cigarettes was initially high, it declined over time, and the majority of adult smokers who began by dual-using ultimately switched completely away from cigarettes 12 months after initial purchase. Additionally, over 60% of dual-users at 12 months substantially reduced their average daily cigarette consumption. Researchers concluded that dual use is often a transitional stage characterized by reductions in cigarette consumption followed by complete switching away from cigarettes.

Juul Labs is fully committed to the Premarket Tobacco Product Application (PMTA) process in the United States, and to that end has built a robust scientific research program to help assess the harm reduction potential of JUUL products, including their impact on the individual user, their ability to move adult smokers away from combustible cigarettes, and the net-population impact on public health. 

We are committed to working cooperatively with regulators, public health officials, and other stakeholders to preserve the historic opportunity to transition adult smokers away from combustible cigarettes, while combating underage use. 

We will continue to share results from our science and research program transparently as we work to support the scientific basis for the category.

About Juul Labs 

Juul Labs’ mission is to transition the world’s billion adult smokers away from combustible cigarettes, eliminate their use, and combat underage usage of our products. We believe that vapor products can offer adult smokers an alternative to combustible cigarettes and, in so doing, reduce the harm associated with tobacco. Nicotine is addictive and can cause certain harms to health. It would be best if no one used any nicotine product. Anyone who smokes should quit. Adult smokers who have not successfully quit should completely switch to potentially less harmful alternative nicotine products. Juul Labs does not want any non-nicotine users, especially those underage, to try our products, as they exist only to transition adult smokers away from combustible cigarettes. JUUL products are not intended to be used for smoking cessation or other therapeutic purposes.

For the general public and policymakers looking for more information about the company, please visit www.juullabs.com.

For scientists, members of the public health community, regulators and policymakers looking to learn more about Juul Labs’ scientific research, please visit www.juullabsscience.com.

*The Society for Research on Nicotine & Tobacco (SRNT) is a separate, unaffiliated entity, and no endorsement has occurred or is implied.

As a part of the Premarket Tobacco Product Application process, Juul Labs has built up its science and evidence-based capabilities with a comprehensive research program focused on examining the public health impact of JUUL System. Our population impact team, in particular, explores the impact of policies and interventions in the United States and globally in order to understand how they can help reduce underage use of nicotine products. 

Our population impact team recently shared a new study entitled “The Impact of Banning ENDS Products on Combustible Cigarette Sales: Initial Evidence from U.S. State-Level Policies” at the 3rd Scientific Summit on Tobacco Harm Reduction, which was held virtually. This new research examined the potential consequences of state-level bans on ENDS products, including their potential impact on cigarette sales in those states — in this case, Massachusetts, Washington, and Rhode Island, all of which passed short-term bans on the sale of ENDS in the fall of 2019. Using commercial data on cigarette sales before and after these bans, our researchers modeled the possible impact of these bans on cigarette sales as compared to what would have been observed in the absence of a ban. 

They found that cigarette sales in states banning ENDS were significantly higher than would have been observed otherwise. In Massachusetts, for example, where a full ban on ENDS products was passed, weekly per capita cigarette sales were 8.3% higher. In Washington and Rhode Island, where flavored ENDS products were banned, higher than expected cigarette sales occurred — 4.6% in Washington and 5% in Rhode Island. 

Overall, researchers estimated that around 3 million additional cigarette packs have been sold during the period of the temporary bans that would not have been sold otherwise, including 1.85 million packs in Massachusetts, 877,000 packs in Washington and 281,000 packs in Rhode Island.

This study provides some of the first evidence that a state’s banning of ENDS products may have unintended consequences, including potentially driving adult smokers back to combustible cigarette use. At the same time, we recognize that the category’s potential will only be realized if we are able to earn a license to operate in society with the trust of regulators, policymakers and other stakeholders. Only if we are a responsible steward of our product and our category and combat underage use, can we help create a world where policies are proportionate to the relative risk of tobacco and nicotine products, thereby ensuring vapor alternatives can compete with combustible cigarettes among adult smokers. 

As part of that process, late last year, Juul Labs, under new leadership, committed to resetting the vapor category. We reduced our product portfolio, halted television, print, and digital product advertising, continued to work with states toward full implementation and enforcement of Tobacco 21 and submitted a Premarket Tobacco Product Application to the U.S. Food and Drug Administration for our Tobacco and Menthol products including comprehensive scientific evidence to support the harm reduction potential of our products and data-driven measures to address underage use. We continue to believe that the FDA’s PMTA process is the right forum to determine the role vapor products can play in helping adult smokers move away from combustible cigarettes and support FDA’s active enforcement against illegally marketed products that jeopardize that potential. 

Juul Labs will continue to share results from its science and research program transparently with the public health communities as it works to support the scientific basis for the category, as well as future regulatory filings. Future research is needed to evaluate the potential spillover effects of these types of local bans, and to determine the long-term impact of these policies on use of tobacco products and net population health.  

About the Study

In this study, researchers utilized Generalized Synthetic Control methods to predict counterfactual cigarette sales for three states that passed temporary bans on ENDS products in 2019: Massachusetts, Rhode Island, and Washington. They compared these counterfactual trends to actual sales in the ban time period in order to assess the impact of these bans on cigarette sales with rigorous causal inference methods.

Overall, the model suggests that the full ban of ENDS in Massachusetts led cigarette sales to be 8.3% (p<0.001) higher than they would have been otherwise. Similar results were seen in states with just flavor bans, ie; in Washington (4.6%, p<0.001) and Rhode Island (5.0%, p<0.001).

Sales of menthol cigarettes were also higher than expected: Actual sales of menthol cigarettes in Massachusetts, Washington and Rhode Island were 12.3%, 6.5%  and 7.1% (p<0.001) higher than predicted by their synthetic counterfactuals. 

The study, entitled, “The Impact of Banning ENDS Products on Combustible Cigarette Sales: Initial Evidence from U.S. State-Level Policies” was presented at the 3rd Scientific Summit on Tobacco Harm Reduction.